Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fotil
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
Fotil is a fixed-dose combination ophthalmic solution containing pilocarpine hydrochloride (a parasympathomimetic/muscarinic receptor agonist) and timolol maleate (a non-selective beta-adrenergic receptor antagonist). Originally developed by Leiras in Finland, the product's development and marketing were continued by Santen following its acquisition of Leiras's ophthalmic business. Fotil is indicated for the treatment of open-angle glaucoma, angle-closure glaucoma, and ocular hypertension. The two active ingredients lower intraocular pressure (IOP) through complementary mechanisms: pilocarpine acts as a miotic to increase aqueous humor outflow by contracting the ciliary muscle, while timolol decreases aqueous humor production by blocking beta-adrenergic receptors in the ciliary epithelium. Fotil is administered as eye drops, typically dosed twice daily.
- Brand names
- FotilFotil ForteFotil sine
- Other names
- FotylFotyl-fortepilocarpine + timololpilocarpine hydrochloride + timolol maleatetimolol + pilocarpinetimolol maleate + pilocarpine hydrochloride
02
Targets
ADRB1 (β1)ADRB2 (β2)M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM3 (M3)CHRM4 (M4)
Beyond the preview
Go deeper on Fotil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fotil.